4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A

SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa

4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics

SparingVision Raises €75 Million Series B

4BIO Capital Portfolio Company Code Biotherapeutics Closes an Oversubscribed $75 Million Series A

4BIO Capital co-leads $30 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science